Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses 29-month follow-up data from the Phase III CheckMate 648 trial (NCT0314315) of first-line nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (ESCC). A total of 970 patients were randomized and initial results demonstrated the superiority of incorporating nivolumab over chemotherapy alone. A longer follow-up additionally shows robust duration of survival in patients receiving nivolumab with ipilimumab and no changes in the safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.